ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
IRVINE, CA, May 2, 2013 – Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone. The MammaPrint Read More
Study shows half of early-stage breast cancer patients may be able to avoid chemotherapy
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
MammaPrint breast cancer test ID’s women who can avoid chemotherapy
KARE, Minneapolis-St.Paul-2013 This TV report tells how you can “know your breast cancer” better through this genomic, personalized medicine test, which is part of the Symphony suite of breast cancer tests.
Study Shows Half of Early-Stage Breast Cancer Patients May Safely Avoid Chemotherapy
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 4, 2013 – The MammaPrint breast cancer test can dramatically reduce the number of women who need to undergo chemotherapy to treat the disease, according to a newly Read More